- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05603312
A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
March 18, 2024 updated by: MeiraGTx, LLC
A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease
The objective of this clinical trial is to evaluate the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The planned length of participation in the study for each participant will be approximately 7 months.
This includes a screening period of up to 40 days, randomization and surgery, and a follow-up period of 26 weeks.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: MeiraGTx Clinical Project Manager
- Phone Number: +44 (0)2038664320
- Email: mgtgad025@meiragtx.com
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University - Yale New Haven Hospital
-
-
Michigan
-
West Bloomfield, Michigan, United States, 48322
- Henry Ford West Bloomfield Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
New York, New York, United States, 10021
- Weill Cornell Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Confirmed Parkinson's Disease
- Levodopa responsiveness for at least 12 months
- UPDRS Part 3 score of ≥25 points in the "off" state
Exclusion Criteria:
- Past history of brain surgery to treat Parkinson's Disease
- Any history of cerebral insult or central nervous system infection
- Atypical Parkinson's Disease
- Focal or lateralized neurologic deficits
- Evidence of significant medical or psychiatric disorders
- Cognitive impairment as defined by Montreal Cognitive Assessment (MoCA)≤20
- Beck Depression Inventory-II score of ≥ 20
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham treatment group
Eligible participants will undergo a sham surgical procedure
|
Sham infusion
|
Experimental: AAV-GAD Dose 1 treatment group
Eligible participants will receive bilateral infusion of AAV-GAD Dose 1 into the STN
|
Bilateral infusion of AAV-GAD Dose 1
|
Experimental: AAV-GAD Dose 2 treatment group
Eligible participants will receive bilateral infusion of AAV-GAD Dose 2 into the STN
|
Bilateral infusion of AAV-GAD Dose 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of AAV-GAD delivered to the STN in patients with Parkinson's Disease
Time Frame: Baseline to Week 26
|
Number of participants with adverse events and serious adverse events
|
Baseline to Week 26
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of AAV-GAD on the Unified Parkinson's Disease Study Rating Scale (MDS-UPDRS) Part 3 (motor function) score in the "off medication state"
Time Frame: Baseline to Week 26
|
mean change from baseline to Weeks 12 and 26 for the AAV-GAD groups compared to the sham group in MDS-UPDRS Part 3 (motor examination) score in the "off" state.
|
Baseline to Week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
October 12, 2022
First Submitted That Met QC Criteria
October 28, 2022
First Posted (Actual)
November 2, 2022
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MGT-GAD-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Sham Surgery
-
Living Cell TechnologiesStatistecol Consultants LimitedCompleted
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
SanBio, Inc.SunovionCompletedChronic Ischemic StrokeUnited States
-
UniQure Biopharma B.V.RecruitingHuntington's DiseaseUnited States
-
Universidade Estadual Paulista Júlio de Mesquita...UnknownGingival RecessionBrazil
-
Universidade Estadual Paulista Júlio de Mesquita...Completed
-
Aarhus University HospitalUnknown
-
Oslo University HospitalKarolinska University HospitalActive, not recruitingSacroiliac Joint Somatic DysfunctionSweden, Norway
-
Brain Neurotherapy Bio, Inc.Recruiting
-
University of DenverCompletedParkinson Disease | SurgeryUnited States